In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.
Lindsay Fischer
Advertisement
Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com
Articles by Lindsay Fischer
Karen Hande, PhD(c), DNP, ANP-BC, CNE, FAANP, ANEF, explains the difference between some of the popular cannabinoid products that patients with cancer may be taking.
In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.
Kelly Goodwin, MSN, RN, ANP-BC, discusses the significance of the recent FDA approvals of capmatinib and trastuzumab deruxtecan for patients with non–small cell lung cancer.
Innovative strategies are needed to ensure that adolescents and young adults with cancer who prefer to die at home are able to make that choice.
Patients with triple-negative breast cancer who received pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores compared with patients who received placebo.
A quality-of-life analysis of the pivotal Destiny-Breast04 trial showed that trastuzumab deruxtecan outperformed physician’s choice of treatment in delaying definitive deterioration.
In the phase 1 SURPASS trial, 72% of patients with solid tumors developed any-grade cytokine release syndrome following an infusion of ADP-A2M4CD8. The median time to resolution was 5 days.
Donna Catamero, ANP-BC, OCN, CCRC, presented on her experience in expanding satellite clinical trial operations during the International Myeloma Society’s 6th Annual Nursing Symposium.
Findings from the SHAWL study found that sexual dysfunction rates are high among women with lung cancer.
The results of the phase 3 MASTERKEY-265 trial show that there is still an unmet need for patients who are refractory to pembrolizumab and anti–PD-1 inhibitors.
The nurse care pathway outlines best practices for monitoring, and responding to, pneumocystis jirovecii pneumonia risk in patients with multiple myeloma receiving novel, high-risk therapies.
The FDA has approved durvalumab for patients with advanced or metastatic biliary tract cancers. The immunotherapy comes with warnings for immune-related adverse events and infusion reactions.
Best management strategies for vancomycin infusion reactions may include premedication, infusion-rate adjustment, and, in some cases, alternative antibiotic therapy.
In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
There is no one-size-fits-all approach to establishing patient-reported outcome measures, according to Hayley Beer, RN.
Younger women who underwent endoscopies had a reduced risk of colorectal cancer incidence, according to findings of a prospective cohort study.
An observational study found no association between single-agent vaginal estrogen therapy or menopausal hormone therapy and increased risk of recurrence or mortality in patients with breast cancer.
Starting patients with unresectable or metastatic renal cell carcinoma on a reduced dose of VEGF tyrosine kinase inhibitor (TKI) therapy did not compromise survival outcomes.
Investigators at Dana-Farber Cancer Institute are developing a virtual frailty assessment, which combines both patient-reported outcomes and standardized performance measures.
Pemigatinib has received FDA approval for relapsed or refractory myeloid/lymphoid neoplasms and FGFR1 rearrangement. Patients receiving pemigatinib will require monitoring for ocular toxicities and high phosphate levels.
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, highlights optimal adverse event management with CD38- and SLAM-F7-directed monoclonal antibodies, XPO-1 inhibitors, and CAR T-cell therapies.
Through patient education tactics, oncology nurses can help patients with multiple myeloma mitigate the oral and dermatologic toxicities associated with talquetamab.
A study presented at the 2022 World Conference on Lung Cancer explored the experiences of patients who received checkpoint inhibition therapy for non–small cell lung cancer.
The FDA has granted olaparib plus abiraterone priority review status for the indication of metastatic castration-resistant prostate cancer.
Hearing loss for cancer survivors is largely underreported, but once identified, is easily treatable, according to Christine Miaskowski, PhD, RN.
Betibeglogene autotemcel is the first FDA-approved cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who need routine blood tranfusions.
An ASCO expert panel conducted a comprehensive literature assessment to determine how diet, weight, and exercise play a role in defining patient outcomes.
Stephanie Jackson, DNP, MSN, RN, AOCNP, BMTCN, discusses the trajectory of targeted and CAR T-cell therapies such as ivosidenib and brexucabtagene autoleucel, and what nurses need to know about these treatments to be able to practice at the top of their licensure.
The FDA has approved trastuzumab deruxtecan for patients with HER2-mutated non–small cell lung cancer after the DESTINY-Lung02 results demonstrated a 57% overall response rate with the agent. The drug comes with warning for interstitial lung disease, neutropenia, and left ventricular dysfunction.
Advertisement
